Abstract
Introduction: The relationship between clinical outcomes and serum anti-TNF levels is controversial. The aim of this study was to perform simultaneous analyses of serum, mucosal and faecal anti-TNF-α levels. Methods: Consecutive IBD patients who received maintenance anti-TNF-α therapy were enrolled. The number of TNF-α positive cells in the mucosa was detected using immunofluorescent labelling on biopsy samples. Serum, mucosal and faecal anti-TNF-α, serum anti-drug antibody and faecal calprotectin levels were determined using ELISA. Each patient underwent body composition analysis as well. Results: Data of 50 patients was analysed. The number TNF-α positive cells was significantly higher in the inflamed than in the un-inflamed part of the colon. Tissue and faecal drug levels did not show any association with serum drug levels, moreover serum anti-TNF concentration did not correlate with endoscopic activity. Mucosal anti-TNF levels were higher only in IFX-treated patients in remission and IFX-treated patients with detectable faecal anti-TNF had lower tissue drug levels. Presence of the drug in the faeces was significantly different according to disease activity. Conclusion: Faecal drug concentration is suggested to be a better predictor of endoscopic activity and loss of response and faecal drug monitoring may improve the estimation accuracy of tissue drug levels.
Funding Information
  • National Research

This publication has 24 references indexed in Scilit: